Temporal variation of onset of relapses in multiple sclerosis is not seasonal: results from the MSBase registry [2008] - 177KB
by OM Gray, D Jolley, C Zwanikken, M Trojano, F Grand’Maison, P Duquette, P Grammond, R Bergamaschi, G Giuliani, R Taffi, RMM Hupperts, T Petersen, C Boz, ME Rio, V Van Pesch, E Roullet, J Lechner-Scott, G Izquierdo, E Cristiano, D Pöhlau, M Fiol, W Oleschko
Background: Previous studies into time of onset of relapses of multiple sclerosis (MS) have been reported with conflicting results. Some have reported that relapses are seasonal, with more relapses in...

Cognitive function in patients with early multiple sclerosis in Asia: data from CogniMS, a worldwide longitudinal study [2008] - 234KB
by KK Kim, Korean CogniMS Study Group, CP Tsai, N Prayoonwiwat, S Fredrikson, EM Wicklein
Background: Cognition is recognized as an important marker for disease evolution in multiple sclerosis (MS) by the scientific community.1 Within the first few years of the disease, cognition has been ...

Anti-aquaporin 4 antibody test in a large series of Japanese optic-spinal multiple sclerosis and neuromyelitis optica [2008] - 161KB
by K Tanaka, T Tani, M Tanaka, M Nishizawa, K Sakimura, M Matsui
Anti-aquaporin 4 antibody (AQP4-Ab) is detected specifically with high sensitivity in optic-spinal form of multiple sclerosis (OSMS)/neuromyelitis optica (NMO). We established the immunofluorescence d...

The seroprevalence of NMO-IgG in Singapore: A pilot study [2008] - 789KB
by K Tan, M Shuguna, KY Goh, SA Lim, T Umapathi
Background: Multiple sclerosis (MS) among Asians is often characterised by severe and selective involvement of the optic nerve and spinal cord and is sometimes called “Asian” optic-spinal MS (OSMS...

Anti-aquaporin-4 antibody positive Sjogren syndrome presenting with recurrent brain involvement [2008] - 234KB
by JH Min, SH Kim, MS Park, KH Lee
Sjogren syndrome can affect the central nervous system and sometimes shows the manifestations of neuromyelitis optica (NMO) with optic neuritis or myelitis. Whereas it used to be said that NMO does no...

Optic neuritis in China [2008] - 181KB
by XJ Zhang, JT Peng, N Jia, XY Yang, WB Wei
Background and Objectives: Optic neuritis is well studied in Western countries. Idiopathic demyelinating optic neuritis (IDON) is considered to be a forme fruste of multiple sclerosis (MS), and has s...

Clinical, laboratory, MRI, and electrophysiologic findings in acute transverse myelitis: Comparison between patients with and without multiple sclerosis [2008] - 1,088KB
by SB Kwon, SH Hwang, S Jung, SY Kang
Background: Acute transverse myelitis (ATM) is a pathogenetically heterogeneous inflammatory disorder affecting the spinal cord at one or more segments. Therefore, the identification of discriminatory...

Baló’s disease showing benign clinical course and co-existence with multiple sclerosis-like lesions in Chinese [2008] - 140KB
by XM Wu, CD Wang, KN Zhang, XF Xie, XH Qu, YQ Xiong, G Huang
Background and Objectives: Baló’s concentric sclerosis is a rare demyelinating disorder usually considered as a variant of multiple sclerosis. The condition often affects young adults and results i...

The Multiple Sclerosis Severity Score (MSSS) re-examined: EDSS rank stability in the MSBase dataset increases 5 years after onset of multiple sclerosis [2008] - 436KB
by OM Gray, D Jolley, C Zwanikken, M Trojano, F Grand’Maison, P Duquette, P Grammond, R Bergamaschi, G Giuliani, R Taffi, RMM Hupperts, T Petersen, C Boz, ME Rio, V Van Pesch, E Roullet, J Lechner-Scott, G Izquierdo, E Cristiano, D Pöhlau, M Fiol, W Oleschko
Background: The Global Multiple Sclerosis Severity Score (MSSS)1 was devised as a comparative multiple sclerosis (MS) population disability assessment tool, to allow comparisons of relative disease se...

Betaferon® in early relapsing-remitting multiple sclerosis surveillance trial (BEST): A combined analysis of patients from Asia completing 2 years of treatment [2008] - 349KB
by KW Lee, BEST Study Group of Korea, J Kira, BEST Study Group of Japan, CP Tsai, T Umapathi, C Meier, L Kappos
Background: IFNB-1b has regulatory approval for use as treatment for relapsing-remitting multiple sclerosis (RRMS) and secondary progressive MS, and for patients with a single demyelinating event, bas...